Schering To Acquire Full U.S. Marketing Rights To Integrilin From Millennium
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal will build on Schering’s foundation in cardiovascular care and provide increased flexibility for sale force effectiveness and promotions, the company says. For Millennium, move will provide a revenue stream to support Velcade and products in development.
You may also be interested in...
Schering-Plough Sets Acquisition Sights On Specialty Products
The company has entered the third – or “turnaround” – phase of its five-point restructuring program.
Schering-Plough Sets Acquisition Sights On Specialty Products
The company has entered the third – or “turnaround” – phase of its five-point restructuring program.
Zetia/Vytorin Capture 12.5% Share Of New Cholesterol-Lowering Scripts
Most of the share gains for the Merck/Schering joint venture are coming at the expense of Pfizer’s Lipitor and Merck’s Zocor, Schering says. Global sales for the joint venture more than doubled to $518 mil. in the second quarter.